Sagimet Biosciences Inc.
$6.44
▲
1.53%
2026-04-21 09:23:00
www.sagimet.com
NGM: SGMT
Explore Sagimet Biosciences Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$206.19 M
Current Price
$6.44
52W High / Low
$11.41 / $2.02
Stock P/E
—
Book Value
$3.42
Dividend Yield
—
ROCE
-51.08%
ROE
-38.2%
Face Value
—
EPS
$-1.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
3.21
Debt / Equity
0.07
Current Ratio
22.82
Quick Ratio
22.82
Forward P/E
-2.78
Price / Sales
—
Enterprise Value
$59.66 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$25.78
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Intensity Therapeutics, Inc. | $5.21 | — | $13.46 M | — | -100.14% | -1.57% | $50 / $4.63 | $4.7 |
| 2. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 3. | NeOnc Technologies Holdings, Inc. | $5.17 | — | $133.03 M | — | 129% | 122.08% | $12.99 / $3.2 | $-0.81 |
| 4. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
| 5. | Taysha Gene Therapies, Inc. | $6.46 | — | $1.85 B | — | -34.88% | -68.45% | $6.5 / $1.13 | $0.87 |
| 6. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 7. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -10.77 M | -14.33 M | -11.93 M | -19.86 M | -18.2 M |
| Net Profit | -9.57 M | -12.91 M | -10.39 M | -18.18 M | -16.2 M |
| EPS in Rs | -0.3 | -0.4 | -0.32 | -0.57 | -0.51 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 2 M | 0 M |
| Operating Profit | -56.89 M | -54.45 M | -30.74 M | -31.05 M |
| Net Profit | -51.04 M | -45.57 M | -27.88 M | -30.5 M |
| EPS in Rs | -1.59 | -1.42 | -0.87 | -0.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 116.48 M | 160.26 M | 96.72 M | 33.03 M |
| Total Liabilities | 5.1 M | 4.45 M | 5.65 M | 219.98 M |
| Equity | 111.38 M | 155.81 M | 91.06 M | -186.95 M |
| Current Assets | 116.4 M | 152.77 M | 96.65 M | 32.79 M |
| Current Liabilities | 5.1 M | 4.45 M | 5.65 M | 5.28 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -45.65 M | -42.44 M | -23.77 M | -24.49 M |
| Investing CF | 4.56 M | -61.68 M | 12.58 M | -32.01 M |
| Financing CF | 0.28 M | 104.82 M | 86.17 M | -0.07 M |
| Free CF | -45.65 M | -42.44 M | -23.77 M | -24.49 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | -63.46% | 8.6% | — | — |
| Profit Margin % | — | -1393.8% | — | — |
| Operating Margin % | — | -1537% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -1537% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.